CUV clinuvel pharmaceuticals limited

Ann: Managing Director Letter to Shareholders, page-3

  1. 34 Posts.
    lightbulb Created with Sketch. 2
    My take:

    • We (CUV) do things differently, we believe our strategy is the right one and we aren't concerned about others negativity.
    • Expect some positive progress on their vitiligo offering in 2025.
    • Interesting, some may even say telling, that he thanks many people but does not thank shareholders in the second from last paragraph showing perhaps a lack of respect for holders. Some may consider this an issue but I don't care if a company loves me back as long as they produce successful drugs to help those in need and make some money in doing so.
    • Definitely a tone of confidence, self-belief and determination in his communication. They are building something special here and LT holders need to keep the faith.

    Biotech success comes from having a good solution for an unmet need, lots of cash and a clear strategy to achieve it. I think we tick these boxes.

    They have kicked one very large goal in the past and seem convinced that further success is only a matter of time.

    I was in early and sold this close to the peak so I have no complaints. Got back in recently. Price may drop further but I sleep a hell of a lot better owning a Biotech with this much money in the bank.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.11
Change
0.220(1.85%)
Mkt cap ! $606.9M
Open High Low Value Volume
$11.93 $12.19 $11.93 $755.6K 62.55K

Buyers (Bids)

No. Vol. Price($)
1 8300 $11.95
 

Sellers (Offers)

Price($) Vol. No.
$12.11 48 1
View Market Depth
Last trade - 16.10pm 28/07/2025 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.